Ontology highlight
ABSTRACT: Background
Ipratropium bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant.Objective
The objective of this study was to evaluate patient satisfaction, device usage, and long-term safety of CVT-R compared to CVT-MDI, and to the simultaneous administration of ipratropium bromide hydrofluoroalkane (HFA; I) and albuterol HFA (A) metered-dose inhalers as dual monotherapies (I + A).Design
This is a 48-week, open-label, randomized, active-controlled, parallel-group study (n = 470) comparing CVT-R to CVT-MDI and to I + A.Participants
Patients were at least 40 years of age, diagnosed with chronic obstructive pulmo
SUBMITTER: Ferguson GT
PROVIDER: S-EPMC3607534 | biostudies-literature | 2013
REPOSITORIES: biostudies-literature